booklet remaking 2016 lr -...

ECNP4th Annual InternationalMood, Psychosis and Anxiety Guideline Congress

29 & 30 April, 2016Conrad Hotel, Dubai

MENAMAT

Saudi Psychiatric Association

MENAMATECNP4th Annual International Mood, Psychosis andAnxiety Treatment Guideline Congress

Golden Sponsor

Silver sponsor

Transportation provide by:

Bronze sponsors:


Table of Contents

Welcome address from the Congress chairpersons

Welcome address continued

Program

Planning Committee

Conference co-chairs

Opening speakers

Plenary speakers

Information on obtaining Continuing Medical Education credits

2

3

4

6

7

8

9

10


Welcome AddressIt is with great pleasure that we announce the “MENAMAT 4th Annual International Treatment Guideline Congress on Mood, Psychosis and Anxiety Disorders” which will be held on April 29 and 30, 2016 at the magnificent New Conrad Hotel – Dubai.

This Congress is MENAMAT 's longest running scientific meeting devoted to exploring the latest research findings related to psychosis and anxiety disorders, as well as focusing on guideline creation. Each year, internationally recognized experts have provided comprehensive reviews of the advances in their areas of expertise.

This year’s Congress will also cover areas such as: the potential role of genetic testing in treatment planning for anxiety disorders and how genes influence response to treatment; early psychosis; problems with cognitive impairments, and the ways these can impact day-to-day functioning in schizophrenia and bipolar patients.

Psychiatric comorbidities are becoming the norm rather than the exception. Depression comorbid with anxiety remains an illusive disorder and lack of early recognition can impact health care negatively. Bipolar disorder is also a disabling psychiatric condition with a very high rate of suicide that needs immediate attention. Epidemiological studies show that anxiety disorders as a group, an important cause of functional impairment, are always found to be the most commonly occurring class of mental disorders. Amongst psychotic illnesses, schizophrenia is a serious but treatable mental illness with significant morbidity and mortality, affecting approximately 0.6% of the general population at some point in their lives. Illness onset is most common in young adults.4 The Congress will utilize the expertise of the European College of Neuropsychopharmacology (ECNP) and a diverse group of opinion leaders both from Europe and North America as well as local and regional experts. ECNP is committed to ensuring that advances in the understanding of brain function and human behavior are translated into better treatments and enhanced public health.

ECNP' s goals:• Support innovative research in the convergent disciplines of neuropsychopharmacology and facilitate the communication of ideas, discoveries and best practices. • Encourage the scientific activities of countries in Europe and co -- ordinate the development of common European standards.• Promote the entry of young scientists into the field and support their ongoing professional development.• Provide guidance and information to the public on matters relating to brain function and the treatment of brain disorders.• Facilitate dialogue with regulators, government bodies, international agencies and industry.


The objective of this meeting is:• To look at an effective implementation strategy by strengthening the message of education of care teams and pro vides feedback of patient data to physicians. Help physicians write more appropriate prescriptions for Psychotropic medication in general and Antipsychotics in particular.• Continuing education as the sole intervention to promote adherence with guidelines and the use of evidence based medicine in the management of psychosis and anxiety disorders. • To help launch good quality studies to determine the effects of implementation strategies in psychiatric services (e.g. feedback, academic detailing, reminders, and audits aimed at changing physician behavior). • The Guidelines describe practical clinical assessment and management strategies tailored to the individual.• To clarify principles to create guidelines to the various cultures and countries of the Middle East and North Africa (MENAMAT).• Finally, to build a collaborative group of leading clinicians and academic s in the Middle East North Africa who will work with MENAMAT to improve the recognition and treatment of major psychiatric disorders? Special lectures and topics at this meeting will cover: • Managing comorbid depression with anxiety.• Managing anxiety disorders in clinical practice.• Use of polypharmacy in resistant depression.• Early psychosis.• Bipolar disorder management.• Managing compliance in schizophrenic patients.• Update on new antipsychotics.• Schizophrenia management between theory and clinical practice.• Anxiety case studies.• Roadmap for developing Middle East and North Africa Guidelines (MENAMAT).

Your participation will undoubtedly contribute to the success of this Congress and will be highly appreciated. I look forward to your dynamic participation and support.

Sincerely yours,

Dr. Hany Shafey

Congress Chairman


Day 1: Friday, April 29, 2016

09:00 - 09:30 Introduction & opening speeches (H.E. Dr. Amin Al Amiri, UAE, H.E. Dr. Maryam Matar, Prof. Hany Shafey, UAE/Canada, Prof. Celso Arango, Spain)

09:30 - 10:15 Depression: the importance of positive and negative affect (Prof. Koen Demyttenaere, Belgium)

10:15 - 10:30 Question Period (Prof. Koen Demyttenaere, Belgium)

10:40 - 11:00 The new framework for MENAMAT: Guidelines for the pharmacological treatment of anxiety disorders (Prof. Hany Shafey, UAE/Canada)

10:30 -10:40 Coffee break

11:00 - 11:45 Progressive brain changes as a marker of worse prognosis after a first psychotic episode and its clinical implications. (Prof. Celso Arango, Spain)

11:45 - 12:15 Question period (Prof. Celso Arango, Spain)

12:15 - 14:00 Lunch and prayer break

14:00 - 15:00 Inflammation/metabolism in the cause and cure of brain illness (Prof. Roger McIntyre, Canada)

15:00 - 15:30 Question period (Prof. Roger McIntyre, Canada)

15:30 - 15:45 Coffee break

15:45 - 16:30 Practical challenges – clinical cases, metabolic differences (Prof. Hany Shafey, UAE/Canada)

16:30 - 17:00 Question period (Prof. Hany Shafey, UAE/Canada


Day 2: Saturday, April 30, 2016

09:00 - 09:15 Introduction & welcome (Prof. Hany Shafey, UAE/Canada & Prof. Celso Arango, Spain)

09:15 - 10:00 Treatment of first episode psychosis, early intervention with LATs (Prof. Celso Arango, Spain)

10:00 - 10:10 Question Period (Prof. Celso Arango, Spain)

10:50 - 11:00 Question Period (Prof. Koen Demyttenaere, Belgium)

10:10 - 10.50 'The intimate relation between depression and anxiety’ (Prof. Koen Demyttenaere, Belgium)

11:45 - 12:30 Cytochrome 450 Middle East metabolic crisis (Prof. Hany Shafey, UAE/Canada

12:30 - 12:45 Question Period (Prof. Hany Shafey, UAE/Canada)

12:45 - 14:00 Lunch break

14:00 - 14:45 ‘Anxiety & Stress: Evidence-Based Best Practices and CBT Treatment Guidelines’ (Michael Hamarneh, PhD, USA)

14:45 - 15:00 Question Period (Michael Hamarneh, PhD, USA)



15:15 - 15:45 WORKSHOP: Psychotic depression – clinical cases

16:45 - 17:00 Question Period

15:45 - 16:45 Open public doctors dialogue (Dr. Maryam Matar, UAE)


Planning committee

Prof. Mahdi Abu-Madini Associate Professor, College of Medicine, Psychiatry Department, University of Dammam, Saudi Arabia.

Prof. Mohammed Hasan Fayek Assistant Head of Psychiatric Department, Rashid Hospital Dubai, UAE.

Dr. Karam Fadhli Wales College of Medicine, Cardiff University. Consultant psychiatrist, Dubai.

Dr. Nadia Guboori American Board-certified Consultant Psychiatrist, Dubai.

Prof. Hany Shafey Clinical Associate Professor of Psychiatry (Adj), University of Western Ontario, Canada. Consultant Psychiatrist, Dubai (Congress Co-Chair).


Opening Speakers

H.E. Dr. Amin Al Amiri Assistant Undersecretary for Public Health Policy and License Sector Chairman of the UAE Supreme National Blood Transfusion Committee

Dr. Al Amiri received his MS in Medical Science (1997) and Ph.D. (2003) from the Faculty of Medicine at Aberdeen University in Scotland, UK. He is responsible for numerous departments at MOH, including:• Public Health Policy Dept.• Drug Control & Registration Dept.• Medical Advertising Dept.• Medical Licensing Dept.• Blood Transfusion & Research.Dr. Al Amiri has received awards from the executive office of the Cooperation Council for the Arab States of the Gulf, the Arab League, and has received the Sheikh Rashid Award for Culture and Science.

H.E. Dr. Maryam Matar Founder and Chairperson, UAE Genetic Diseases Association (UAEGDA)

Dr. Maryam Matar is the Chairman and Founder of the UAE Genetic Diseases Association, launched in 2006, which has achieved many outstanding successes under her leadership. She is the Deputy Chairperson of Dubai Cares, which works to improve children's access to quality primary education in developing countries. In 2015, Dr. Maryam was selected as The International Alliance for Women (TIAW) World of Difference 100 Award recipient under the Public Service/Government Category, for her contributed to the economic empowerment of women. In the same year she received an Achievers Award as one of the most powerful women in Middle East and first woman in the field of genetic research & CSR from UNASCO- UAE. Additionally, she was ranked 33 of the list of "100 most powerful Arab under 40" in Science by the magazine "Arabian Business" in April 2015. The U.S. Department of State honored Dr. Maryam as an outstanding woman in science in the Middle East--North Africa region, for the year 2015. In 2014, Dr. Maryam Matar was listed among the 20 Most Influential Women in Science in the Islamic world. She was awarded by The International Alternative Investment Review (IAIR) magazine the prestigious title of the IAIR AWARDS Woman of the Year – with support from the European Commission. In 2012, Dr. Maryam Matar was ranked first in the UAE and fourth in the Arab world in Sciences and Research category of the most powerful Arab women in 2012 by the Arabian Business magazine. Her abilities have also honored her to be a Board Member of the Global Strategic Initiative on Advanced Radiation Medical Science, Vienna/Austria (NGO GSI-ARMS). Dr. Maryam was selected by the Arab League's Scientific and Humanitarian Development Program of the Arab Women Organization (AWO) as ambassador of Goodwill for Women and Children for 2012-2012 in the Arab world.


Conference Co-Chairs

Prof. Hany Shafey Dr. Shafey is Clinical Associate Professor (Adj.) with the University of Western Ontario, Canada. He continues to carry such designation while working here in the Middle East. He is a highly experienced adult psychiatrist and a subspecialist in children and adolescents. Dr. Shafey trained at the prestigious University of Toronto in Canada. He is Canadian Board-certified in psychiatry and a Fellow of the Royal College of Physicians and Surgeons of Canada since 1985. He is a Member of the College of Physicians and Surgeons of Ontario and a Member of the American Academy of Child and Adolescent Psychiatry. He has been licensed to practice medicine in Ontario, Canada, since 1981 as well as in the Commonwealth of Virginia, USA, since March 1992. He is also licensed to practice medicine in Dubai (both with Dubai Healthcare City and DOHMS) since 2007. Dr. Shafey has been an Examiner for the Medical Council of Canada (a licensing examination body for physicians to practice medicine in Canada) from 1993 to 1997 and an Examiner for the Saudi Board of Psychiatry from December 2001, 2002 and 2003. Dr. Shafey is a known international presenter and speaker, having received many awards including Best Professor at his university in 1992. He was selected as the highest rated speaker amongst international presenters in Dubai (Harvard Medical School) in Nov 2007. In addition to working in Canada for over 16 years, he has worked in the Middle East for approximately 16 years and became the chief of psychiatry in one of the leading facilities in the region (Aramco Services Company), which is accredited by the Joint Commission International for hospital accreditation. Starting in April 2010 he became a consultant psychiatrist at the Emirates Hospital Dubai Marina branch and the Dubai Mall medical center.

Prof. Celso Arango Celso Arango, MD, PhD is a psychiatrist and Adjunct Professor of Psychiatry at the University of Maryland in Baltimore and Full Professor of Psychiatry at the Universidad Complutense in Madrid. He is also Head of the Child and Adolescent Department of Psychiatry at Hospital General Universitario Gregorio Marañón. Dr. Arango is the Scientific Director of the Spanish Psychiatric Research Network, with25 centers and more than 400 researchers. He is also Coordinator of the Child and Adolescent First-Episode Psychosis Study (CAFEPS) funded by the Spanish Ministry of Health (with eight centers in Spain) and the Child and Adolescent Neuropsychiatry Network funded by the European College of Neuropsychopharmacology (ECNP). He has written more than 280 peer-reviewed articles, 7 books, and more than 40 book chapters. Many of his articles and book chapters have focused on the neurobiology of early-onset and first-episode psychoses as well as the safety of psychiatric medications in pediatric patients. In addition, his group has shown how patients with a first psychotic episode experience greater losses of gray matter than expected and a correlation of gray matter loss with antioxidant status. Dr. Arango has participated in more than 69 competitively funded research projects, as Principal Investigator in 55of them, including projects with international funding (Stanley Foundation, NARSAD, European Commission, etc.) and several clinical drug trials. He is also coordinator of several multicenter projects that assess multiple prognostic factors and treatment in early-onset psychosis, and is currently participating in eight EU projects funded by the VII Framework.


Plenary Speakers

Prof. Koen Demyttenaere Prof. Koen Demyttenaere is professor at the faculty of Medicine of the Katholieke Universiteit Leuven in Belgium and currently chair of the University Psychiatric Center at the university. Prof. Demyttenaere is a specialist in depression and anxiety. His main interest fields are compliance with antidepressants, scales in depression and anxiety, quality of life and epidemiology of depression and anxiety. He has published over 190 international papers and book chapters, and he is member of several international advisory boards in the field of antidepressants. Prof. Demyttenaere is a memer of the Committee for Ethics on Dual Use of Research, the Council of the Faculty of Medicine, the Council of the Department of Neurosciences, and an invited member of the Board of the Department of Neurosciences.

Prof. Roger McIntyre Dr. Roger McIntyre is Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning.

Dr. Michael Hamarneh Dr. Michael Hamarneh is a Consultant Clinical Psychologist with Mediclinic (City Hospital & Dubai Mall). He is a US-educated and trained Consultant Clinical Psychologist with a long-standing career and significant expertise in clinical and behavioral health psychology, Industrial / Organizational (I/O) psychology, Occupational Stress Management and Occupational Health and Safety. He is a Licensed Psychologist in the US and in UAE by Dubai Healthcare City (DHCC) & Dubai Health Authority (DHA). As a Consultant Clinical Psychologist, he has long-standing interest and extensive experience in working with individuals and families from various cultures who suffer from a wide range of psychological disorders and problems in living. He has become became a recognized and sought-after speaker in the area of cultural sensitivity as he tirelessly promoted tolerance, understanding, respect and healing among all people. Dr. Hamarneh holds a Bachelor’s degree in psychology from the University of Texas at Austin, a Master’s degree in clinical psychology from the University of Houston, and a Ph. D. (Doctorate) in counseling psychology from the University of Florida.


CME CreditsInformation on obtaining Continuing Medical Education credits The European Accreditation Committee in CNS (EACIC) has granted 12 CME credits to this Congress.

HOW TO OBTAIN CME CREDITS

Participants requesting CME credits are required to complete the online evaluation form on the EACIC website www.eacic.eu.

Please follow the below steps to receive your CME Certificate.

1. Go to the EACIC website www.eacic.eu2. Click on the CME logo (in the blue bar on the right hand side of the webpage)3. Choose the option "I am already registered" or "I am not registered"4. Log on or register5. Choose the option 1 "I want to evaluate an accredited event"6. Choose the event for which you would like to receive CME credits7. Complete the online evaluation form8. Press "save"9. Your CME certificate will be automatically emailed to the address provided

The deadline to complete the evaluation form is 30 June 2016.

European Accreditation Committee in CNS (EACIC)

Scientific secretariat: Dr Daniel Souery

47, avenue Jacques Pastur | 1180 Brussels | Belgium

Mobile phone number: +32 479987440

E-mail: [email protected] | Website: www.eacic.eu


The organizers of the MENAMAT 4th Annual Mood, Psychosis and Anxiety Treatment Guideline Implementation Congress 2016 would like to thank the following organizations for their valuable support:

Saudi Psychiatric Association

booklet remaking 2016 lr -...

Documents